1.Early Administration of Nelonemdaz May Improve the Stroke Outcomes in Patients With Acute Stroke
Jin Soo LEE ; Ji Sung LEE ; Seong Hwan AHN ; Hyun Goo KANG ; Tae-Jin SONG ; Dong-Ick SHIN ; Hee-Joon BAE ; Chang Hun KIM ; Sung Hyuk HEO ; Jae-Kwan CHA ; Yeong Bae LEE ; Eung Gyu KIM ; Man Seok PARK ; Hee-Kwon PARK ; Jinkwon KIM ; Sungwook YU ; Heejung MO ; Sung Il SOHN ; Jee Hyun KWON ; Jae Guk KIM ; Young Seo KIM ; Jay Chol CHOI ; Yang-Ha HWANG ; Keun Hwa JUNG ; Soo-Kyoung KIM ; Woo Keun SEO ; Jung Hwa SEO ; Joonsang YOO ; Jun Young CHANG ; Mooseok PARK ; Kyu Sun YUM ; Chun San AN ; Byoung Joo GWAG ; Dennis W. CHOI ; Ji Man HONG ; Sun U. KWON ;
Journal of Stroke 2025;27(2):279-283
2.Early Administration of Nelonemdaz May Improve the Stroke Outcomes in Patients With Acute Stroke
Jin Soo LEE ; Ji Sung LEE ; Seong Hwan AHN ; Hyun Goo KANG ; Tae-Jin SONG ; Dong-Ick SHIN ; Hee-Joon BAE ; Chang Hun KIM ; Sung Hyuk HEO ; Jae-Kwan CHA ; Yeong Bae LEE ; Eung Gyu KIM ; Man Seok PARK ; Hee-Kwon PARK ; Jinkwon KIM ; Sungwook YU ; Heejung MO ; Sung Il SOHN ; Jee Hyun KWON ; Jae Guk KIM ; Young Seo KIM ; Jay Chol CHOI ; Yang-Ha HWANG ; Keun Hwa JUNG ; Soo-Kyoung KIM ; Woo Keun SEO ; Jung Hwa SEO ; Joonsang YOO ; Jun Young CHANG ; Mooseok PARK ; Kyu Sun YUM ; Chun San AN ; Byoung Joo GWAG ; Dennis W. CHOI ; Ji Man HONG ; Sun U. KWON ;
Journal of Stroke 2025;27(2):279-283
3.Early Administration of Nelonemdaz May Improve the Stroke Outcomes in Patients With Acute Stroke
Jin Soo LEE ; Ji Sung LEE ; Seong Hwan AHN ; Hyun Goo KANG ; Tae-Jin SONG ; Dong-Ick SHIN ; Hee-Joon BAE ; Chang Hun KIM ; Sung Hyuk HEO ; Jae-Kwan CHA ; Yeong Bae LEE ; Eung Gyu KIM ; Man Seok PARK ; Hee-Kwon PARK ; Jinkwon KIM ; Sungwook YU ; Heejung MO ; Sung Il SOHN ; Jee Hyun KWON ; Jae Guk KIM ; Young Seo KIM ; Jay Chol CHOI ; Yang-Ha HWANG ; Keun Hwa JUNG ; Soo-Kyoung KIM ; Woo Keun SEO ; Jung Hwa SEO ; Joonsang YOO ; Jun Young CHANG ; Mooseok PARK ; Kyu Sun YUM ; Chun San AN ; Byoung Joo GWAG ; Dennis W. CHOI ; Ji Man HONG ; Sun U. KWON ;
Journal of Stroke 2025;27(2):279-283
4.Device Closure or Antithrombotic Therapy After Cryptogenic Stroke in Elderly Patients With a High-Risk Patent Foramen Ovale
Pil Hyung LEE ; Jung-Sun KIM ; Jae-Kwan SONG ; Sun U. KWON ; Bum Joon KIM ; Ji Sung LEE ; Byung Joo SUN ; Jong Shin WOO ; Soe Hee ANN ; Jung-Won SUH ; Jun Yup KIM ; Kyusup LEE ; Sang Yeub LEE ; Ran HEO ; Soo JEONG ; Jeong Yoon JANG ; Jang-Whan BAE ; Young Dae KIM ; Sung Hyuk HEO ; Jong S. KIM
Journal of Stroke 2024;26(2):242-251
Background:
and Purpose In young patients (aged 18–60 years) with patent foramen ovale (PFO)- associated stroke, percutaneous closure has been found to be useful for preventing recurrent ischemic stroke or transient ischemic attack (TIA). However, it remains unknown whether PFO closure is also beneficial in older patients.
Methods:
Patients aged ≥60 years who had a cryptogenic stroke and PFO from ten hospitals in South Korea were included. The effect of PFO closure plus medical therapy over medical therapy alone was assessed by a propensity-score matching method in the overall cohort and in those with a high-risk PFO, characterized by the presence of an atrial septal aneurysm or a large shunt.
Results:
Out of the 437 patients (mean age, 68.1), 303 (69%) had a high-risk PFO and 161 (37%) patients underwent PFO closure. Over a median follow-up of 3.9 years, recurrent ischemic stroke or TIA developed in 64 (14.6%) patients. In the propensity score-matched cohort of the overall patients (130 pairs), PFO closure was associated with a significantly lower risk of a composite of ischemic stroke or TIA (hazard ratio [HR]: 0.45; 95% confidence interval [CI]: 0.24–0.84; P=0.012), but not for ischemic stroke. In a subgroup analysis of confined to the high-risk PFO patients (116 pairs), PFO closure was associated with significantly lower risks of both the composite of ischemic stroke or TIA (HR: 0.40; 95% CI: 0.21–0.77; P=0.006) and ischemic stroke (HR: 0.47; 95% CI: 0.23–0.95; P=0.035).
Conclusion
Elderly patients with cryptogenic stroke and PFO have a high recurrence rate of ischemic stroke or TIA, which may be significantly reduced by device closure.
5.Developing a national surveillance system for stroke and acute myocardial infarction using claims data in the Republic of Korea: a retrospective study
Tae Jung KIM ; Hak Seung LEE ; Seong-Eun KIM ; Jinju PARK ; Jun Yup KIM ; Jiyoon LEE ; Ji Eun SONG ; Jin-Hyuk HONG ; Joongyub LEE ; Joong-Hwa CHUNG ; Hyeon Chang KIM ; Dong-Ho SHIN ; Hae-Young LEE ; Bum Joon KIM ; Woo-Keun SEO ; Jong-Moo PARK ; Soo Joo LEE ; Keun-Hwa JUNG ; Sun U. KWON ; Yun-Chul HONG ; Hyo-Soo KIM ; Hyun-Jae KANG ; Juneyoung LEE ; Hee-Joon BAE
Osong Public Health and Research Perspectives 2024;15(1):18-32
Objectives:
Limited information is available concerning the epidemiology of stroke and acute myocardial infarction (AMI) in the Republic of Korea. This study aimed to develop a national surveillance system to monitor the incidence of stroke and AMI using national claims data.
Methods:
We developed and validated identification algorithms for stroke and AMI using claims data. This validation involved a 2-stage stratified sampling method with a review of medical records for sampled cases. The weighted positive predictive value (PPV) and negative predictive value (NPV) were calculated based on the sampling structure and the correspondingsampling rates. Incident cases and the incidence rates of stroke and AMI in the Republic ofKorea were estimated by applying the algorithms and weighted PPV and NPV to the 2018National Health Insurance Service claims data.
Results:
In total, 2,200 cases (1,086 stroke cases and 1,114 AMI cases) were sampled from the 2018 claims database. The sensitivity and specificity of the algorithms were 94.3% and 88.6% for stroke and 97.9% and 90.1% for AMI, respectively. The estimated number of cases, including recurrent events, was 150,837 for stroke and 40,529 for AMI in 2018. The age- and sex-standardized incidence rate for stroke and AMI was 180.2 and 46.1 cases per 100,000 person-years, respectively, in 2018.
Conclusion
This study demonstrates the feasibility of developing a national surveillance system based on claims data and identification algorithms for stroke and AMI to monitor their incidence rates.
6.Molluscum Contagiosum Mimicking Verruca Vulgaris on the Sole
Seung Hui SEOK ; Moon Soo YOON ; Jung U SHIN
Annals of Dermatology 2023;35(Suppl1):S144-S145
7.Differences in Pandemic-Related Factors Associated with Alcohol and Substance Use among Korean Adolescents: Nationwide Representative Study.
Hyunju YON ; Sangil PARK ; Jung U SHIN ; Ai KOYANAGI ; Louis JACOB ; Lee SMITH ; Chanyang MIN ; Jinseok LEE ; Rosie KWON ; Guillaume FOND ; Laurent BOYER ; Sunyoung KIM ; Namwoo KIM ; Sang Youl RHEE ; Jae Il SHIN ; Dong Keon YON ; Ho Geol WOO
Biomedical and Environmental Sciences 2023;36(6):542-548
8.Clinical Characteristics and Antibiotic Susceptibility of Staphylococcus lugdunensis Isolated from Skin Diseases: A Retrospective Single-Center Study
Yun Kyung JANG ; Hee Jung LEE ; Dong Hyun KIM ; Moon Soo YOON ; Jung U SHIN
Korean Journal of Dermatology 2023;61(2):124-129
Background:
Staphylococcus lugdunensis is an emerging pathogen in skin and soft tissue infections. However, until recently, the role of S. lugdunensis as a skin pathogen remained underrated.
Objective:
The purpose of this study was to investigate the clinical characteristics and antibiotic susceptibility of S.lugdunensis isolated from skin diseases.
Methods:
This is a retrospective chart review of 48 cases in which S. lugdunensis was isolated from bacterial skin cultures between 2016 and 2021.
Results:
Among the 48 patients, the mean age was 41.0 years, 54.2% were male, and 12.5% of the patients had immunosuppressive diseases. Nearly 87.4% of infections occurred below the waist and the dominant sources of isolation were epidermal cyst (31.3%) and hidradenitis suppurativa (29.2%). The rate of resistance of S. lugdunensis against β-lactam antibiotics were as follows: penicillin, 83.3%; oxacillin, 37.5%; and methicillin, 29.2%.
Conclusion
S. lugdunensis is emerging as one of the primary pathogens of skin infections. When S. lugdunensis is isolated, dermatologists should consider that it is not just a component of the skin flora but can also be a pathogen. If S. lugdunensis is identified as the cause of infection, it should be managed with appropriate antibiotic therapy.
9.A Case of Pembrolizumab-Induced Toxic Epidermal Necrolysis
Go Woon CHOI ; Hee Jung LEE ; Dong Hyun KIM ; Moon Soo YOON ; Jung U SHIN
Korean Journal of Dermatology 2022;60(2):120-124
Pembrolizumab is an immune checkpoint inhibitor that selectively blocks the programmed cell death (PD)-1 receptor. Although it has a dramatic effect on the treatment of advanced malignancies, instability of immune tolerance may cause immune-related adverse events in the skin. A 62-year-old male with a history of metastatic urothelial carcinoma was referred to the dermatology department and presented with a widespread mucocutaneous rash. Itching appeared 7 days after the first administration of pembrolizumab, and on the third day after the second administration, an erythematous maculopapular rash that coalesced into large flaccid bullae on the whole body with a positive Nikolsky’s sign developed. A biopsy revealed a subepidermal bulla with basal keratinocyte necrosis. Pembrolizumab was discontinued due to the diagnosis of toxic epidermal necrolysis (TEN), and intravenous methylprednisolone was started. Herein, we report a case of TEN induced by pembrolizumab to highlight immune-related cutaneous adverse events in patients receiving anti-PD-1 therapy.
10.Toker Cell Hyperplasia in Zuska’s Disease Mimicking Paget’s Disease: A Case Report
Yun Kyung JANG ; Sung Eun CHOI ; Ji Hee KIM ; Soo Chan KIM ; Hee Jung LEE ; Dong Hyun KIM ; Moon Soo YOON ; Jung U SHIN
Korean Journal of Dermatology 2022;60(8):527-531
Toker cells are epithelial cells, consisting of pale cytoplasm with a polygonal or oval shape. They are found in 10% of the nipple epidermis and require differentiation from Paget cells. However, the Toker cell hyperplasia observed in Zuska’s disease can be difficult to distinguish from Paget cells. In this case report, a 17-year-old girl presented with recurrent erythematous erosion of the right areola. Biopsy specimens showed numerous large epidermal cells with abundant pale cytoplasm. Immunohistochemical staining for CK7 and estrogen receptor were positive, whereas that of HER2/NEU and Ki-67 were negative. Breast ultrasonography showed signs of abscesses and fistulas without suspicious findings of underlying breast cancer. Based on these findings, the patient was diagnosed with Zuska’s disease with Toker cell hyperplasia. Herein, we report a case of Toker cell hyperplasia in Zuska’s disease, thereby highlighting the need to differentiate Toker cells from Paget cells based on clinical, histological, and immunohistochemical characteristics.

Result Analysis
Print
Save
E-mail